Notice of the forthcoming Retina UK AGM – July 2025
Formal notice of the forthcoming Annual General Meeting in July 2025.
Search
Search results
Notice of the forthcoming Retina UK AGM – July 2026
Formal notice of the forthcoming Annual General Meeting in July 2026.
News: Notice of the forthcoming Retina UK AGM – September 2024
Formal notice of the forthcoming Annual General Meeting in September 2024.
Notice of the forthcoming Retina UK AGM – July 2022
This year the AGM will be held on Saturday, 9 July at 4.00pm:
Trusts and Foundations
Inherited retinal dystrophies (IRDs) are the leading cause of blindness in working-age people in the UK, and children as young as eighteen-months are regularly diagnosed.
What we do
Our vision is a world where everyone with inherited sight loss is able to live a fulfilling life.
Beacon gene therapy VISTA trial reports positive results for X-linked retinitis pigmentosapositive results for X-linked retinitis pigmentosa
Beacon Therapeutics has announced positive results from its phase 2/3 VISTA trial of laru-zova, an experimental gene therapy for X-linked retinitis pigmentosa (XLRP). The findings mark a significant step forward for a condition that currently has no approved treatments.
Every experience counts: Insights from our sight loss survey
A huge thank you to everyone who completed our 2025 sight loss survey. This year we received over 600 responses. It follows similar surveys in 2019 and 2022 which led directly to the introduction of our Unlock Genetics and Discover Wellbeing resources, as well as shaping our work with the professional community who support people with inherited sight loss.
Johnson & Johnson gene therapy update – What happens now?
The latest research news from Retina UK.